Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Retatrutide Regulatory Status Retatrutide occupies a unique position because it is not yet FDA-approved: Not FDA-approved currently in Phase 3 clinical trials with Eli Lilly No prescription pathway in the US yet no Mounjaro/Wegovy equivalent for retatrutide Legal as research chemical sold in the US for in-vitro and animal research under research-use-only labeling Likely to receive FDA approval in coming years if clinical trial endpoints meet expectations WADA status currently not specifically listed, though peptide hormones generally fall under WADA categories Not DEA-scheduled no controlled substance status Unlike semaglutide and tirzepatide, retatrutide does not yet exist as a prescription drug
GHK-Cu: The Budget-Friendly Alternative Copper peptide GHK-Cu is the least expensive option in this class, with monthly costs of $80 to $180 for subcutaneous injection and as low as $30 to $80 for topical formulations
If an HRA is integrated with a group health plan that does not meet the minimum value standard, then the HRA can only reimburse certain items, such as copayments, coinsurance, deductibles, premiums, and medical care that is not considered essential health benefits
David Arterburn, MD, MPH, is busy these days exceptionally busy
It demonstrates wound healing acceleration in skin injuries
